← All trials
NCT04592458
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2020
- Primary completion
- Nov 30, 2022
- Completion date
- Nov 30, 2024
- First posted
- Oct 19, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BGI GroupLead sponsor
- Shenzhen UniversityCollaborator
- Shenzhen UniversityOverall official - principal investigator
- BGI GroupOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.